Lausanne University Hospital (CHUV)
Lausanne, 1011, Switzerland
NCT Number: NCT04642534
For women of reproductive age, the overall postpartum weight retention (weight gain between pregnancies) plays a significant role in long-term obesity. With 20% of women retaining ≥ 5 kg at 12 months postpartum, the risk of developing conditions, such as gestational diabetes mellitus (GDM), metabolic syndrome (MS) and subsequently diabetes and cardiovascular diseases, is substantially increased. In post-GDM mothers (women who had GDM in their recent pregnancy), postpartum weight retention is also an essential predictor of future diabetes.
Recent studies have identified the impact of circadian rhythms (influencing sleep/wake cycles) and diurnal rhythm of eating (when and how often calories are consumed over a 24h period) on cardio-metabolic disorders. In women, one remarkable feature of the postpartum period is an 'externally imposed' circadian misalignment of both sleep and eating rhythms, because most babies take several weeks to months to establish their daily pattern of activity and feeding, which is particularly relevant for breastfeeding women, as the responsibility is generally on the mother.
The overarching goal of this project is to explore the interplay between the diurnal rhythm of eating, circadian and metabolic parameters in humans. The potential postpartum effects of circadian disruption will be unraveled in women who had GDM during their pregnancy and those with an uneventful pregnancy. These women are subject to a circadian misalignment due to their 'externally imposed' changes in sleep/wake cycles and eating times in the postpartum period.
With a comprehensive approach combining molecular characterization of in vivo and in vitro circadian clock parameters along with metabolic, endocrine, transcriptomic, and lipidomic studies, the investigators will assess if eating duration and/or circadian misalignment impact on circadian clock parameters of postpartum women in a prospective cohort of 6 months.
Looking for future studies?
Notify Me18 year–40 year
Female
Observational
Lausanne, 1011, Switzerland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Duration from the first to last caloric intake over 24-hour cycle
Time frame: At baseline
Measured in cultured skin fibroblasts
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by actigraphy
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by the Pittsburgh Sleep Quality Index (scale 0-21, 0 indicating no sleeping difficulty, 21 indicating severe sleeping difficulties)
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by bioelectrical impedance analysis
Time frame: Changes between baseline and the close-out visit (i.e.changes between Month 0 and Month 6)
Measured by bioelectrical impedance analysis
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by bioelectrical impedance analysis
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by actigraphy
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by clinical chemistry
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by clinical chemistry
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by continuous glucose monitoring
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Insulin and thyroid-stimulating hormone (mIU/L)
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Cortisol (nmol/L)
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by high-throughput mass spectrometry lipidomics
Time frame: Changes between baseline and the close-out visit (i.e. changes between Month 0 and Month 6)
Measured by high-throughput mass spectrometry metabolomics
University of Lausanne Hospitals
Other
Molecular and Functional Interplay Between the Circadian Clocks and Eating Patterns in Patients With Cardio-metabolic Diseases (Cohort)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06911372
Diabetes Mellitus, Diabetes, Gestational
Iowa City, Iowa, United States
View Trial DetailsNCT03120208
Depression, Postpartum, Depressive Disorder
Clermont-Ferrand, France
View Trial DetailsNCT07657819
Adherence Interventions, Behavior
Ankara, Turkey (Türkiye)
View Trial DetailsNCT06811285
Fatigue, Mood (Psychological Function)
Uşak, Turkey (Türkiye)
View Trial Details